December 1, 2025

Company Name: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Security Code: 7575; TSE Prime Market)
Inquiries: Takeyoshi Egawa, Director and CFO
(TEL. +81-3-6711-5200)

Japan Lifeline Issues Integrated Report 2025

TOKYO, JAPAN – December 1, 2025 – Japan Lifeline Co., Ltd. (“the Company”) announces that it has published its "Integrated Report 2025" and made it available on the Company’s website.

■ Integrated Report 2025 (English version) *Link to the publication page

Takeyoshi Egawa, Director and CFO of the Company, stated that the document communicates both financial and non-financial information to stakeholders regarding the Group’s initiatives for sustainable value creation. He noted that "Integrated Report 2025" details growth strategies for global expansion to achieve the Medium-Term Management Plan targets revised upward in May 2025. These updates are presented through messages with the CEO, COO, and CFO, alongside ones from business division heads.

Furthermore, the report highlights the corporate vision and human resource strategy, specifically focusing on empowering young employees and enhancing training environments to support growth. The CFO concluded that the Company remains committed to increasing corporate value through comprehensive information disclosure and strengthened stakeholder dialogue.





About Japan Lifeline

Japan Lifeline Co., Ltd. (Tokyo Stock Exchange Prime Market: 7575) is a medical device company specializing in the cardiac and cardiovascular fields. The company focuses primarily on electrophysiology catheters and vascular grafts. It builds its product portfolio through distribution operations that introduce superior overseas medical devices to Japan. The company also develops and produces proprietary products through its manufacturing capabilities. Operating through 48 domestic sales offices while expanding its proprietary products globally, Japan Lifeline provides the latest and most suitable medical devices to healthcare professionals and patients worldwide. For more information, visit https://www.japanlifeline.com/.